---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-052324"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:35:31.549238+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# DMAA SPAC signs $1B deal to merge with AI/analytics firm Power Analytics Global

## Summary
- Definitive merger agreement with Power Analytics Global (PAGC) at target enterprise value of $1.0B; floor of $300M.
- Post-close ownership: ~90% to PAGC shareholders, ~10% to existing DMAA shareholders pre-PIPE dilution.
- Minimum cash target at closing of $30M (floor $15M) from trust account and/or PIPE financing.
- Merger subject to DMAA shareholder approval, SEC S-4 effectiveness, and Nasdaq listing of surviving entity.
- Two amendments on April 30, 2026 corrected governing law to Delaware and completed notice address provisions.

## SEC filing metadata
- accession: 0001213900-26-052324
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/0001213900-26-052324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/ea0289172-8k425_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-052324
- JSON: https://secwatch.observer/filing/0001213900-26-052324.json
- Plain text: https://secwatch.observer/filing/0001213900-26-052324.txt

## Source-grounded claims
- claim_id: 5430c22678e33216fd6f3b976489fa9fc7750da5
  claim: Drugs Made In America Acquisition Corp. amended Amendment No. 1 to the Merger Agreement with Power Analytics Global Corp valued at revised governing law and jurisdiction provisions, clarified termination provisions, revised notice (effective 2026-04-30).
  evidence_excerpt: On April 30, 2026, DMAA and PAGC entered into Amendment No. 1 to the Merger Agreement (“Amendment No. 1”) for the purpose of correcting certain inconsistencies and incomplete items in the Merger Agreement prior to public disclosure.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/0001213900-26-052324-index.htm
- claim_id: 89b8385363a1150e7b4c9c8d63b7e80e0a5827a3
  claim: Drugs Made In America Acquisition Corp. amended Amendment No. 2 to the Merger Agreement with Power Analytics Global Corp valued at completed notice address provisions including street addresses and email addresses (effective 2026-04-30).
  evidence_excerpt: Also on April 30, 2026, DMAA and PAGC entered into Amendment No. 2 to the Merger Agreement (“Amendment No. 2,” and together with Amendment No. 1, the “Amendments”) for the purpose of completing the notice address provisions set forth in Section 11.1, including the parties’ respective street addresses and email addresses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/0001213900-26-052324-index.htm
- claim_id: d1fd890485699fe2bf3eec38be4913d16eb3192e
  claim: Drugs Made In America Acquisition Corp. entered into Definitive Merger Agreement with Power Analytics Global Corp valued at target enterprise valuation of $1.0 billion, Floor Valuation of $300 million, post-closing ownership (effective 2026-04-29).
  evidence_excerpt: On April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Merger Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/0001213900-26-052324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.